Griffin ups Hana's price target to $15

Hana Biosciences, Inc. was maintained by Griffin Securities, Inc. analyst Chrystyna Bedrij at a buy rating, but the price target was increased to $15. Further details were not released. Shares of the South San Francisco, Calif., biopharmaceutical company were down 4 cents, or 0.67%, at $5.90 on volume of 38,900 shares. A three-month average of share volume was not available.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.